Brendon Neuen
@brendonneuen.bsky.social
Nephrologist; Associate Professor; Program Lead, Renal & Metabolic, George Institute; Director, Kidney Trials, Royal North Shore Hospital; Secretariat, #SMART-C; Podcast host, #KidneyCompass
www.SMART-C.net
www.SMART-C.net
Reposted by Brendon Neuen
16 is same as last year
someone check if I have missed anything
Read our blogs here www.nephjc.com/news/kidneyw...
#NephJC #KidneyWk
@nephroseeker.medsky.social @brendonneuen.bsky.social
someone check if I have missed anything
Read our blogs here www.nephjc.com/news/kidneyw...
#NephJC #KidneyWk
@nephroseeker.medsky.social @brendonneuen.bsky.social
Kidney Week in Houston: Day 1 — NephJC
in this edition: Atacicept in IgAN; Albuminuria as a surrogate outcome, Renal Remission and additional CONFIDENCE analysis
www.nephjc.com
November 9, 2025 at 11:31 PM
16 is same as last year
someone check if I have missed anything
Read our blogs here www.nephjc.com/news/kidneyw...
#NephJC #KidneyWk
@nephroseeker.medsky.social @brendonneuen.bsky.social
someone check if I have missed anything
Read our blogs here www.nephjc.com/news/kidneyw...
#NephJC #KidneyWk
@nephroseeker.medsky.social @brendonneuen.bsky.social
Reposted by Brendon Neuen
In the afternoon another late breaking oral session among other things at 4:30 pm
@brendonneuen.bsky.social
Lorundrostat
A new oral GLP1
REMODEL to understand sema mechanism
GBD kidney disease with @paddymark.bsky.social
And
@cervantes-lily1.bsky.social !
#KidneyWk
@brendonneuen.bsky.social
Lorundrostat
A new oral GLP1
REMODEL to understand sema mechanism
GBD kidney disease with @paddymark.bsky.social
And
@cervantes-lily1.bsky.social !
#KidneyWk
November 7, 2025 at 10:39 AM
In the afternoon another late breaking oral session among other things at 4:30 pm
@brendonneuen.bsky.social
Lorundrostat
A new oral GLP1
REMODEL to understand sema mechanism
GBD kidney disease with @paddymark.bsky.social
And
@cervantes-lily1.bsky.social !
#KidneyWk
@brendonneuen.bsky.social
Lorundrostat
A new oral GLP1
REMODEL to understand sema mechanism
GBD kidney disease with @paddymark.bsky.social
And
@cervantes-lily1.bsky.social !
#KidneyWk
From the Lancet 2022 paper:
But I agree it is worth drilling down a bit more (it is on the to-do list)
But I agree it is worth drilling down a bit more (it is on the to-do list)
October 21, 2025 at 9:32 AM
From the Lancet 2022 paper:
But I agree it is worth drilling down a bit more (it is on the to-do list)
But I agree it is worth drilling down a bit more (it is on the to-do list)
Reposted by Brendon Neuen
October 17, 2025 at 9:49 PM
Reposted by Brendon Neuen
October 17, 2025 at 9:49 PM
Reposted by Brendon Neuen
It’s all live now!
Apart from the two trials mentioned above
We have 5 more sessions at #KidneyWk + posters
High Impact Trials 1 on Friday AM in plenary hall
Apart from the two trials mentioned above
We have 5 more sessions at #KidneyWk + posters
High Impact Trials 1 on Friday AM in plenary hall
October 17, 2025 at 9:49 PM
It’s all live now!
Apart from the two trials mentioned above
We have 5 more sessions at #KidneyWk + posters
High Impact Trials 1 on Friday AM in plenary hall
Apart from the two trials mentioned above
We have 5 more sessions at #KidneyWk + posters
High Impact Trials 1 on Friday AM in plenary hall
Reposted by Brendon Neuen
Join us December 8-10, Washington DC! Full programme here: www.globalcvctforum.com/scientific-p...
CVCT Global Forum Scientific Program 2025
Discover the unique high science & discussion program for CVCT 2025 (Global CardioVascular Trialists Forum), December 8-10, at the Mayflower Hotel, Washington DC
www.globalcvctforum.com
September 2, 2025 at 1:26 PM
Join us December 8-10, Washington DC! Full programme here: www.globalcvctforum.com/scientific-p...
Reposted by Brendon Neuen
Interesting slide #BucketOfColdWater
September 23, 2025 at 7:41 PM
Interesting slide #BucketOfColdWater
Reduction in all-cause hospitalisation driven by fewer admissions for:
- Cardiac
- Renal
- Metabolic disorders, and
- Infections
Interestingly reduction in infections also observed with semaglutide in the FLOW trial - could GDMT improve physical resilience & susceptibility to infections?
- Cardiac
- Renal
- Metabolic disorders, and
- Infections
Interestingly reduction in infections also observed with semaglutide in the FLOW trial - could GDMT improve physical resilience & susceptibility to infections?
July 15, 2025 at 9:16 PM
Reduction in all-cause hospitalisation driven by fewer admissions for:
- Cardiac
- Renal
- Metabolic disorders, and
- Infections
Interestingly reduction in infections also observed with semaglutide in the FLOW trial - could GDMT improve physical resilience & susceptibility to infections?
- Cardiac
- Renal
- Metabolic disorders, and
- Infections
Interestingly reduction in infections also observed with semaglutide in the FLOW trial - could GDMT improve physical resilience & susceptibility to infections?